CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0776
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Antitumor Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora a Kinase

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2007English

TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

International Journal of Cancer
Cancer ResearchOncology
2019English

GSK1070916, a Potent Aurora B/C Kinase Inhibitor With Broad Antitumor Activity in Tissue Culture Cells and Human Tumor Xenograft Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Cancer Research
Cancer ResearchOncology
2018English

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy